BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

NCT02880618 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-04-20

No results posted yet for this study

Summary

The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

Conditions

Interventions

DEVICE

Barostim Neo™ System

Sponsors & Collaborators

  • CVRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Jochen Müller-Ehmsen, PhD · Asklepios Klinik Altona

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-13
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880618 on ClinicalTrials.gov